ニューロウジェネスィス
Neurogene Inc.
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -1.39 | $0 | -$26M |
| 2025 Q4 | -1.60 | $0 | -$17M |
| 2025 Q3 | -0.99 | $0 | -$20M |
| 2025 Q2 | -1.05 | $0 | -$20M |
| 2025 Q1 | -1.08 | $0 | -$22M |
| 2024 Q4 | -1.31 | $0 | -$18M |
| 2024 Q3 |
| -1.19 |
| $0 |
| -$16M |
| 2024 Q2 | -1.09 | $925,000 | -$16M |